Cargando…
Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy
BACKGROUND: Prior studies have evaluated the use of various constituents of cannabis for their anti-seizure effects. Specifically, cannabidiol, a non-psychoactive component of cannabis, has been investigated for treatment-resistant epilepsy, but more information is needed particularly on its use in...
Autores principales: | Wheless, James W., Dlugos, Dennis, Miller, Ian, Oh, D. Alexander, Parikh, Neha, Phillips, Steven, Renfroe, J. Ben, Roberts, Colin M., Saeed, Isra, Sparagana, Steven P., Yu, Jin, Cilio, Maria Roberta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534520/ https://www.ncbi.nlm.nih.gov/pubmed/31049885 http://dx.doi.org/10.1007/s40263-019-00624-4 |
Ejemplares similares
-
Long‐term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open‐label extension trial
por: Thiele, Elizabeth A., et al.
Publicado: (2021) -
Efficacy and Tolerance of Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy
por: Klotz, Kerstin A., et al.
Publicado: (2019) -
Cannabidiol in the Treatment of Epilepsy
por: von Wrede, Randi, et al.
Publicado: (2021) -
Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program
por: Contin, Manuela, et al.
Publicado: (2021) -
Dispensary Cannabidiol (CBD): Nothing to Worry About!
por: Elliott, Taylor, et al.
Publicado: (2023)